- The LNA Gapmer specifically targets gastrin mRNA in CCK-BR positive cancer cells, reducing tumor growth。
- The use of LNA chemistry ensures the Gapmer's stability and longevity in vivo, leading to sustained therapeutic effects。
- Preclinical studies show significant reduction in tumor growth and metastasis in pancreatic cancer models using receptor-targeted LNA Gapmers。
OVERVIEW
This invention presents a novel therapeutic approach for treating CCK-BR positive cancers, with a primary focus on pancreatic cancer. It features the use of Locked Nucleic Acid (LNA) Gapmers—antisense oligonucleotides (ASOs) designed to selectively downregulate gastrin mRNA, a key driver in pancreatic cancer growth. These LNA Gapmers are engineered for high stability and longevity in vivo, ensuring effective RNA interference. The technology incorporates a peptide or DNA aptamer that specifically targets the cholecystokinin-B receptor (CCK-BR), which is overexpressed in pancreatic cancer cells, thereby enhancing the specificity and efficacy of the treatment. Preclinical studies have demonstrated that this receptor-targeted LNA Gapmer significantly inhibits tumor growth and metastasis in animal models of human pancreatic cancer, offering a promising alternative to current chemotherapy treatments.
BACKGROUND
Pancreatic cancer is one of the most lethal malignancies, projected to become the second leading cause of cancer-related deaths within the next decade. Current treatment options are limited and largely ineffective, with chemotherapy being the only approved therapy for advanced stages. However, chemotherapy is associated with significant toxicity and poor response rates. This invention addresses the urgent need for more effective and targeted treatment strategies for pancreatic cancer, particularly for tumors that do not respond to existing immune-based therapies.
Benefit
Provides a targeted therapy that selectively attacks cancer cells, minimizing off-target effects.Demonstrates high stability and a long half-life, which enhances its effectiveness in vivo.Offers a less toxic alternative to chemotherapy, reducing the side effects associated with traditional treatments.Shows potential for application in other CCK-BR positive cancers, expanding the scope of its therapeutic impact.
Market Application
Treatment of advanced pancreatic cancer with a targeted, less toxic approach compared to traditional chemotherapy.Potential application in other CCK-BR positive cancers, such as colon, liver, gastric, esophageal, small cell lung, and medullary thyroid cancers.Could be integrated into personalized cancer therapy regimes, particularly for patients with CCK-BR positive tumors.Offers a new avenue for developing cancer treatments that leverage RNA interference technologies.
Publications
US Patent Application Filed
TARGET-SPECIFIC LNA GAPMERS DECREASE GROWTH AND METASTASES OF PANCREATIC CANCER, May 2024, 166(5):S-1332-S-1333, DOI:10.1016/S0016-5085(24)03508-X
LNA gapmer to gastrin inhibits growth and metastases of human pancreatic cancer in mice, March 2024, Cancer Research 84(6_Supplement):3250-3250, 84(6_Supplement):3250-3250, DOI:10.1158/1538-7445.AM2024-3250
Our mission is to advance GU’s innovations through strategic alliances and new venture creation, to facilitate the translation of research breakthroughs into tangible solutions, and to cultivate a dynamic and inclusive environment for entrepreneurship. We advance this mission in support of the GU community and for the benefit of society.
Create your free account to connect with Georgetown University and thousands of other innovative organizations and professionals worldwide
Send a request for information
to Georgetown University
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
